Our Development Pipeline
Topical Minocycline, 1%
BPX-04 (topical minocycline, 1%) is being developed for the treatment of moderate-to-severe papulopustular rosacea. In a Phase 2b study, BPX-04 was shown to be well tolerated and demonstrated efficacy in reducing the number of facial inflammatory lesions among patients. BPX-04 is a topical gel formulation of fully solubilized minocycline.
If you are interested in any of Timber’s ongoing clinical research programs, please contact firstname.lastname@example.org.